Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients
Title:
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients
Author:
Clavio, Marino Vignolo, Luana Albarello, Alessandra Varaldo, Riccardo Pierri, Ivana Catania, Gioacchino Balocco, Manuela Michelis, Gianluca Miglino, Maurizio Manna, Annunziata Balleari, Enrico Carella, A. Michele Sessarego, Mario Van Lint, Maria Teresa Bacigalupo, Andrea Gobbi, Marco